ProCE Banner Activity

EFFORT: Phase II Study of the WEE1 Inhibitor Adavosertib ± Olaparib in PARPi-Resistant Ovarian Cancer

Slideset Download
Conference Coverage
Adavosertib with or without olaparib demonstrated clinical activity with a manageable toxicity profile in patients with PARPi-resistant ovarian cancer, regardless of BRCA status.

Share

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme